These findings suggest that VacT2BP holds promise as a drug delivery system for AML treatment, leveraging TLR2‐mediated immune stimulation and efficient drug transport to enhance therapeutic efficacy and overcome drug resistance [26], shown in Table 2. The gene discussed is TLR2; the disease is acute myeloid leukemia.